Drug
GLP-1 Mimetic clinical trials
Keep track of what changes. Save the GLP-1 Mimetic studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2020 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 17
The Affiliated Hospital of Xuzhou Medical University (2) · PegBio Co., Ltd. (2) · Peking University Third Hospital (2) · Lia Bally (1) · GRADE Study Group (1) · Tanabe Pharma Corporation (1) · Sciwind Biosciences APAC CO Pty. Ltd. (1) · Kowa Company, Ltd. (1)
Often tested with
Tested in the same studies.
Sodium-Glucose Transporter 2 Inhibitors (2) · Hormone Replacement Therapy (1) · Glimepiride (1) · Sitagliptin (1) · Insulin Glargine (1) · Canagliflozin (1) · Tofogliflozin (1) · Metformin (1)
Studies
Open first, then newest update. How each study uses GLP-1 Mimetic is read from its arms, and is right about nine times in ten.
Testing it · 20
- Impact GLP-1 Agonists Following BariatricRecruitingPhase 4University of Missouri-ColumbiaNCT06132477Written as GLP-1 receptor agonist
- Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOSNot yet recruitingNot applicablePeking University Third HospitalNCT07687667Written as GLP-1 receptor agonist
- SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial CancerNot yet recruitingPhase 4Hospital Universitari de BellvitgeNCT07462663Written as GLP-1 Receptor Agonist
- GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)RecruitingPhase 2Chinese University of Hong KongNCT05356104Written as GLP-1 receptor agonist
- Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist TherapyRecruitingPhase 2University of VirginiaNCT06903923Written as GLP-1 receptor agonist
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesRecruitingPhase 4Brigham and Women's HospitalNCT05390892Written as GLP-1 receptor agonist
- Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal CancerNot yet recruitingPhase 2St. James's Hospital, IrelandNCT07314528Written as GLP-1 receptor agonist
- Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DMRecruitingNot applicableThe Affiliated Hospital of Xuzhou Medical UniversityNCT06256419Written as GLP-1 receptor agonist
- Effects of GLP-1RAs on Reproductive Outcomes in PCOS and ObesityNot yet recruitingNot applicablePeking University Third HospitalNCT06775093Written as GLP-1 receptor agonist
- Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose HomeostasisActive, not recruitingNot applicableLia BallyNCT06715514Written as GLP-1 Receptor Agonist
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesCompletedPhase 3GRADE Study GroupNCT01794143Written as GLP-1 receptor agonist (liraglutide)
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusCompletedPhase 4Tanabe Pharma CorporationNCT02227849Written as GLP-1 analogue
- Effect of GLP-1 Receptor Agonists on Trabecular Bone ScoreTerminatedPhase 2University of Mississippi Medical CenterNCT04964388Written as GLP-1 receptor agonist
- Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DMCompletedNot applicableThe Affiliated Hospital of Xuzhou Medical UniversityNCT05037045Written as GLP-1 receptor agonist
- Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin MonotherapyCompletedPhase 3PegBio Co., Ltd.NCT04504396Written as GLP-1 receptor agonist
- Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM SubjectsCompletedPhase 3PegBio Co., Ltd.NCT04504370Written as GLP-1 receptor agonist
- To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult ParticipantsCompletedPhase 1Sciwind Biosciences APAC CO Pty. Ltd.NCT04389775Written as Cohort A
- Tofogliflozin GLP-1 Analogue Combination TrialCompletedPhase 4Kowa Company, Ltd.NCT02537834Written as GLP-1 analogue
- Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?CompletedNot applicableUniversity of California, San FranciscoNCT02846233Written as GLP1 receptor agonist
- Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM PatientsStatus unknownPhase 4Dasman Diabetes InstituteNCT04135287Written as GLP-1 receptor agonist